Obesity
Showing NaN - NaN of 26
Overweight, Obesity and Diabetes, Type 2 Trial (Cagrilintide, Semaglutide, Placebo cagrilintide)
Not yet recruiting
- Overweight
- +2 more
- Cagrilintide
- +3 more
-
Concord, California
- +147 more
Jan 24, 2023
Overweight, Obesity Trial in Worldwide (Semaglutide, Placebo (semaglutide))
Active, not recruiting
- Overweight
- Obesity
- Semaglutide
- Placebo (semaglutide)
-
Birmingham, Alabama
- +804 more
Dec 19, 2022
Obesity Trial in Worldwide (Semaglutide, Placebo (semaglutide))
Active, not recruiting
- Obesity
- Semaglutide
- Placebo (semaglutide)
-
Fairhope, Alabama
- +97 more
Jun 15, 2022
Obesity, Overweight Trial in Worldwide (Tirzepatide, Placebo)
Active, not recruiting
- Obesity
- Overweight
- Tirzepatide
- Placebo
-
Huntington Park, California
- +64 more
Mar 22, 2022
Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (Semaglutide, Placebo)
Completed
- Metabolism and Nutrition Disorder
- Obesity
- Semaglutide
- Placebo
-
Anniston, Alabama
- +71 more
Jan 7, 2022
Obesity, Overweight Trial in Worldwide (Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide))
Completed
- Obesity
- Overweight
- Semaglutide 1.0 mg
- +3 more
-
Buena Park, California
- +146 more
Nov 8, 2021
Obesity, Surgery, Quality of Life Trial in United Kingdom (Gastric Band, Gastric Bypass, Sleeve Gastrectomy)
Recruiting
- Obesity
- +3 more
- Gastric Band
- +2 more
-
Birmingham, United Kingdom
- +11 more
Oct 7, 2021
Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (semaglutide, liraglutide, )
Completed
- Metabolism and Nutrition Disorder
- Obesity
- semaglutide
- +2 more
-
Anaheim, California
- +73 more
Apr 14, 2020
Obesity Trial in Worldwide (JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3)
Completed
- Obesity
- JNJ-64565111 Dose Level 1
- +4 more
-
Phoenix, Arizona
- +50 more
Jan 14, 2020
Cardiovascular Disease, High Cardiovascular Risk, Obesity Trial in Worldwide (Lorcaserin HCl, Placebo)
Completed
- Cardiovascular Disease
- +4 more
- Lorcaserin hydrochloride
- Placebo
-
Alexander City, Alabama
- +498 more
Jun 27, 2019
Obesity Trial in United States (S-2367 Placebo, S-2367 800 mg, S-2367 1600 mg)
Completed
- Obesity
- S-2367 Placebo
- +3 more
-
Mobile, Alabama
- +37 more
May 8, 2018
Obesity Trial in United States (S-2367 (velneperit))
Completed
- Obesity
- S-2367 (velneperit)
-
Birmingham, Alabama
- +72 more
Apr 26, 2018
Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (liraglutide, )
Completed
- Metabolism and Nutrition Disorder
- Obesity
- liraglutide
- placebo
-
Birmingham, Alabama
- +225 more
Dec 20, 2017
Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (liraglutide, )
Completed
- Metabolism and Nutrition Disorder
- Obesity
- liraglutide
- placebo
-
Vestavia Hills, Alabama
- +160 more
Dec 6, 2017
Obesity, Cardiovascular Diseases Trial in United States (Naltrexone HCl/Bupropion HCl ER, Placebo)
Terminated
- Obesity
- Cardiovascular Diseases
- Naltrexone HCl/Bupropion HCl ER
- Placebo
-
Alexander City, Alabama
- +138 more
Feb 21, 2017
Obesity Trial in Worldwide (Placebo, CP-945,598, CP-945,598 Treatment B)
Terminated
- Obesity
- Placebo
- +2 more
-
Birmingham, Alabama
- +90 more
Nov 5, 2012
Obesity Trial in Canada, United States (CP-945,598 Treatment A, CP-945,598 Treatment B, Placebo)
Terminated
- Obesity
- CP-945,598 Treatment A
- +2 more
-
Fairhope, Alabama
- +81 more
Nov 5, 2012
European Study of Cardiovascular Risk
Completed
- Cardiovascular Risk Factors
- +5 more
-
Alland, Austria
- +777 more
Oct 28, 2009